Parkside Financial Bank & Trust’s Beam Therapeutics BEAM Stock Holding History

Parkside Financial Bank & Trust’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$858	Hold	25	–	–	﹤0.01%	2451
2026 Q1	$596	Hold	25	–	–	﹤0.01%	2522
2025 Q4	$693	Buy	+25	New	+$638	﹤0.01%	2474
2025 Q3	–	Sell	-30	Closed	-$511	–	2723
2025 Q2	$511	Buy	30 +10	+50%	+$174	﹤0.01%	2536
2025 Q1	$391	Buy	+20	New	+$524	﹤0.01%	2549

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Parkside Financial Bank & Trust's BEAM Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 25 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Parkside Financial Bank & Trust first reported a position in BEAM in Q1 2025 and has held it in 5 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Parkside Financial Bank & Trust held 25 shares of Beam Therapeutics worth $858 as of Q2 2026.
Parkside Financial Bank & Trust left its Beam Therapeutics share count unchanged in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2451 holding.
Parkside Financial Bank & Trust first reported a position in Beam Therapeutics in Q1 2025 and has held it in 5 quarters since.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.